Outcomes of Re-Treatment with First-Line Trastuzumab Plus Taxane in Patients (pts) with Metastatic Breast Cancer (mbc) Who Relapsed after (neo)adjuvant Trastuzumab: A Prospective Multicenter Study.
Binghe Xu,Xi-Chun Hu,Hong Zheng,Xiaojia Wang,Qingyuan Zhang,Shude Cui,Donggeng Liu,Ning Liao,Rongcheng Luo,Qiang Sun,Shiying Yu
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e12068
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e12068 Background: Trastuzumab combined with chemotherapy is the backbone of HER2-positive early breast cancer (eBC) and mBC treatment. In the pivotal phase III study H0648g, all enrolled pts with mBC were trastuzumab-naive. There is limited data about efficacy and safety of trastuzumab retreatment of relapsed pts exposed to trastuzumab-based therapy. Here, we performed a prospective, single arm, multicenter trial to assess efficacy and safety profile of trastuzumab and taxane combination in pts with HER2-positive mBC who relapsed after prior (neo)adjuvant trastuzumab-based therapy. Methods: Pts with HER2-positive mBC who had completed (neo)adjuvant trastuzumab treatment for ≥ 9 weeks, with a relapse-free interval ≥ 6 months after trastuzumab treatment in the (neo)adjuvant setting for eBC were enrolled. 32 eligible pts were assigned to receive trastuzumab (weekly), in combination with paclitaxel (weekly) or docetaxel (every 3 weeks) until disease progression, unacceptable toxicity, death or withdrawal from study. The primary endpoint was progression free survival (PFS). The secondary endpoints included overall response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), time to progression (TTP), overall survival (OS) and safety profile. Results: The median PFS was 9.9 months (95%CI, 6.28-13.63), ORR (CR+PR) was 81.3% (95%CI, 63.6%-92.8%), CBR (CR+PR+SD ≥ 6 months) was 81.3% (95%CI, 63.6%-92.8%), median DOR was 9.8 months (95%CI, 5.82-11.60), median TTP was 9.9 months (95%CI, 6.28-13.63), 5 pts in the enrolled 32 pts (15.6%) had the event of death and median OS has not been reached. The most common adverse events (AEs, all grades) were blood and lymphatic system disorders, 5 subjects (15.6%, 5/32) had occurrence of serious AEs (SAEs). No congestive heart failure or any unexpected trastuzumab-related SAEs were reported. Conclusions: Re-treatment with trastuzumab plus taxane as first-line therapy is an effective regimen for pts with HER2-positive mBC who relapsed after (neo)adjuvant trastuzumab for eBC. The safety profile was good and the adverse reactions were tolerable and manageable. Clinical trial information: NCT01301729.